- Home
- ALVR vs HSPO Comparison
ALVR vs HSPO Comparison
Compare ALVR & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- HSPO
- Stock Information
- Founded
- ALVR 2013
- HSPO 2014
- Country
- ALVR United States
- HSPO United States
- Employees
- ALVR N/A
- HSPO N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- HSPO Blank Checks
- Sector
- ALVR Health Care
- HSPO Finance
- Exchange
- ALVR Nasdaq
- HSPO Nasdaq
- Market Cap
- ALVR 87.7M
- HSPO 87.7M
- IPO Year
- ALVR 2020
- HSPO 2022
- Fundamental
- Price
- ALVR $0.94
- HSPO $11.25
- Analyst Decision
- ALVR Sell
- HSPO
- Analyst Count
- ALVR 5
- HSPO 0
- Target Price
- ALVR $1.00
- HSPO N/A
- AVG Volume (30 Days)
- ALVR 155.6K
- HSPO 27.4K
- Earning Date
- ALVR 11-04-2024
- HSPO 01-01-0001
- Dividend Yield
- ALVR N/A
- HSPO N/A
- EPS Growth
- ALVR N/A
- HSPO N/A
- EPS
- ALVR N/A
- HSPO 0.33
- Revenue
- ALVR N/A
- HSPO N/A
- Revenue This Year
- ALVR N/A
- HSPO N/A
- Revenue Next Year
- ALVR N/A
- HSPO N/A
- P/E Ratio
- ALVR N/A
- HSPO $34.26
- Revenue Growth
- ALVR N/A
- HSPO N/A
- 52 Week Low
- ALVR $0.58
- HSPO $10.60
- 52 Week High
- ALVR $2.49
- HSPO $11.25
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- HSPO 69.42
- Support Level
- ALVR $0.74
- HSPO $11.17
- Resistance Level
- ALVR $0.91
- HSPO $11.25
- Average True Range (ATR)
- ALVR 0.06
- HSPO 0.00
- MACD
- ALVR 0.01
- HSPO 0.00
- Stochastic Oscillator
- ALVR 94.50
- HSPO 100.00
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.